Potassium Chloride side effects: what 113,160 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Potassium Chloride Extended-Release
Who reports
113,160 reports · 73% serious · 15,936 with death outcome · 63% female
Used for
Potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
What it is
Potassium chloride is a metal chloride salt with a K(+) counterion. It has a role as a NMR chemical shift reference compound and a fertilizer.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,157 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vaginal flatulence | 183 | 279.4 221.9–351.9ROR 279.9 · calibrated p 3e-11 ✓ | 109.5 EB05 96.8 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=183 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Appendicolith | 206 | 221.5 180.7–271.4ROR 221.9 · calibrated p 2e-10 ✓ | 99.5 EB05 88.6 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious n=206 · ♀ 0% (drug 63%) · 100% clinician | no trial arm names this drug |
| Sleep disorder therapy | 97 | 202.6 151.7–270.6ROR 202.8 · calibrated p 8e-10 ✓ | 94.6 EB05 79.8 · IC025 +5.7 3/3 methods agree | Reporting / coding artifact | serious n=97 · ♀ 0% (drug 63%) · 100% clinician | no trial arm names this drug |
| Analgesic therapy | 92 | 79.2 62.0–101.2ROR 79.3 · calibrated p 9e-7 ✓ | 54.9 EB05 46.1 · IC025 +5.1 3/3 methods agree | Reporting / coding artifact | serious n=92 · ♀ 0% (drug 63%) · 100% clinician | no trial arm names this drug |
| Drug therapy | 85 | 66.9 52.1–85.7ROR 66.9 · calibrated p 3e-6 ✓ | 48.6 EB05 40.6 · IC025 +4.9 3/3 methods agree | Reporting / coding artifact | serious n=85 · ♀ 0% (drug 63%) · 100% clinician | no trial arm names this drug |
| Device maintenance issue | 93 | 36.4 29.2–45.5ROR 36.4 · calibrated p 1e-4 ✓ | 30.3 EB05 25.5 · IC025 +4.4 3/3 methods agree | Reporting / coding artifact | ♀ 100% (drug 63%) · 100% consumer | no trial arm names this drug |
| Female genital tract fistula | 205 | 24.9 21.5–28.8ROR 25.0 · calibrated p 7e-4 ✓ | 22.0 EB05 19.6 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=204 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Chronic kidney disease-mineral and bone disorder | 109 | 20.8 17.0–25.3ROR 20.8 · calibrated p 0.002 ✓ | 18.7 EB05 15.9 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=109 | no trial arm names this drug |
| Radiculopathy | 252 | 19.5 17.1–22.2ROR 19.5 · calibrated p 0.002 ✓ | 17.7 EB05 15.9 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=252 · ♀ 88% (drug 63%) | no trial arm names this drug |
| Hyperparathyroidism secondary | 219 | 17.5 15.2–20.0ROR 17.5 · calibrated p 0.004 ✓ | 16.0 EB05 14.3 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=218 | no trial arm names this drug |
| Infusion site discharge | 144 | 16.9 14.3–20.1ROR 17.0 · calibrated p 0.004 ✓ | 15.5 EB05 13.5 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=79 · ♀ 100% (drug 63%) · 100% consumer | no trial arm names this drug |
| Nephrogenic anaemia | 392 | 16.9 15.2–18.7ROR 16.9 · calibrated p 0.004 ✓ | 15.5 EB05 14.3 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=392 | no trial arm names this drug |
| Hyperphosphataemia | 174 | 16.5 14.1–19.2ROR 16.5 · calibrated p 0.005 ✓ | 15.2 EB05 13.4 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=173 · ♀ 0% (drug 63%) · 100% clinician | no trial arm names this drug |
| Cardioactive drug level increased | 109 | 16.5 13.5–20.0ROR 16.5 · calibrated p 0.005 ✓ | 15.1 EB05 12.9 · IC025 +3.5 3/3 methods agree | Lab value / disease marker | serious n=106 | no trial arm names this drug |
| Chronic sinusitis | 278 | 14.8 13.1–16.7ROR 14.8 · calibrated p 0.008 ✓ | 13.7 EB05 12.4 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=274 · ♀ 100% (drug 63%) | no trial arm names this drug |
| Left atrial dilatation | 93 | 14.4 11.6–17.8ROR 14.4 · calibrated p 0.009 ✓ | 13.3 EB05 11.1 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=93 · ♀ 0% (drug 63%) | no trial arm names this drug |
| Proctitis | 201 | 14.2 12.3–16.4ROR 14.3 · calibrated p 0.009 ✓ | 13.2 EB05 11.7 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=201 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Oesophageal spasm | 122 | 13.1 10.9–15.7ROR 13.1 · calibrated p 0.013 ✓ | 12.2 EB05 10.4 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=119 · ♀ 100% (drug 63%) | no trial arm names this drug |
| Infusion site infection | 148 | 12.9 10.9–15.2ROR 12.9 · calibrated p 0.013 ✓ | 12.0 EB05 10.4 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=82 · ♀ 100% (drug 63%) · 100% consumer | no trial arm names this drug |
| Blood phosphorus increased | 174 | 12.6 10.8–14.7ROR 12.6 · calibrated p 0.015 ✓ | 11.7 EB05 10.3 · IC025 +3.3 3/3 methods agree | Lab value / disease marker | serious n=171 · ♀ 0% (drug 63%) · 100% clinician | no trial arm names this drug |
| Orthopnoea | 198 | 12.2 10.6–14.1ROR 12.2 · calibrated p 0.016 ✓ | 11.4 EB05 10.1 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=189 | no trial arm names this drug |
| Metabolic alkalosis | 96 | 11.8 9.6–14.5ROR 11.8 · calibrated p 0.019 ✓ | 11.0 EB05 9.2 · IC025 +3.1 3/3 methods agree | Likely indication confounding term in indications | serious n=94 · 100% clinician | no trial arm names this drug |
| Infusion site haemorrhage | 189 | 11.4 9.9–13.2ROR 11.4 · calibrated p 0.021 ✓ | 10.7 EB05 9.5 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=78 · 100% consumer | no trial arm names this drug |
| Hypervolaemia | 279 | 11.4 10.1–12.8ROR 11.4 · calibrated p 0.021 ✓ | 10.7 EB05 9.7 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=269 | no trial arm names this drug |
| Device infusion issue | 136 | 10.8 9.1–12.9ROR 10.8 · calibrated p 0.025 ✓ | 10.1 EB05 8.8 · IC025 +3.0 3/3 methods agree | Reporting / coding artifact | 100% consumer | no trial arm names this drug |
| Haemorrhagic anaemia | 247 | 10.8 9.5–12.3ROR 10.8 · calibrated p 0.025 ✓ | 10.2 EB05 9.1 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=247 | no trial arm names this drug |
| Aortic stenosis | 192 | 10.7 9.3–12.4ROR 10.8 · calibrated p 0.026 ✓ | 10.1 EB05 8.9 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=191 · ♀ 36% (drug 63%) | no trial arm names this drug |
| Rebound acid hypersecretion | 163 | 10.3 8.8–12.1ROR 10.4 · calibrated p 0.029 ✓ | 9.7 EB05 8.5 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=163 | no trial arm names this drug |
| Therapeutic agent toxicity | 178 | 10.2 8.8–11.9ROR 10.3 · calibrated p 0.030 ✓ | 9.6 EB05 8.5 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=177 | no trial arm names this drug |
| Ischaemic cardiomyopathy | 156 | 9.8 8.3–11.5ROR 9.8 · calibrated p 0.036 ✓ | 9.2 EB05 8.0 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=156 · ♀ 0% (drug 63%) | no trial arm names this drug |
| Blood chloride decreased | 129 | 9.6 8.1–11.5ROR 9.6 · calibrated p 0.038 ✓ | 9.0 EB05 7.8 · IC025 +2.9 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=124 · 100% clinician | no trial arm names this drug |
| Essential hypertension | 128 | 9.6 8.0–11.4ROR 9.6 · calibrated p 0.039 ✓ | 9.0 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=119 | no trial arm names this drug |
| Oxygen consumption increased | 116 | 9.5 7.9–11.5ROR 9.5 · calibrated p 0.040 ✓ | 8.9 EB05 7.6 · IC025 +2.8 3/3 methods agree | Lab value / disease marker | serious n=95 · ♀ 100% (drug 63%) | no trial arm names this drug |
| Hypokalaemia (low potassium) | 2,213 | 9.3 8.9–9.7ROR 9.5 · calibrated p 0.038 ✓ | 8.9 EB05 8.6 · IC025 +3.1 3/3 methods agree | Likely indication confounding term in indications | age-adj. PRR 7.6 · serious PRR 7.1 | no trial arm names this drug |
| Brain natriuretic peptide increased | 148 | 9.3 7.9–11.0ROR 9.3 · calibrated p 0.042 ✓ | 8.7 EB05 7.6 · IC025 +2.8 3/3 methods agree | Lab value / disease marker | serious n=144 | no trial arm names this drug |
| Right ventricular failure | 339 | 9.3 8.3–10.4ROR 9.3 · calibrated p 0.042 ✓ | 8.8 EB05 8.1 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious PRR 7.0 | no trial arm names this drug |
| Blood potassium decreased | 1,386 | 8.9 8.4–9.4ROR 9.0 · calibrated p 0.046 ✓ | 8.5 EB05 8.1 · IC025 +3.0 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 6.9 · serious PRR 6.6 | no trial arm names this drug |
| Colitis microscopic | 215 | 8.8 7.7–10.1ROR 8.9 · calibrated p 0.049 ✓ | 8.4 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=215 · ♀ 100% (drug 63%) | no trial arm names this drug |
| Lymphoedema | 316 | 8.8 7.9–9.9ROR 8.9 · calibrated p 0.049 ✓ | 8.4 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=283 | no trial arm names this drug |
| Infusion site pain | 579 | 8.7 8.1–9.5ROR 8.8 · calibrated p 0.050 ✓ | 8.4 EB05 7.8 · IC025 +2.9 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 6.3 · serious n=240 · 85% consumer | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Heart failure | 4,278 | 4.54.4–4.6 | signal |
| Gi bleeding | 3,661 | 3.83.6–3.9 | signal |
| Arrhythmia / qt | 3,809 | 3.73.6–3.8 | signal |
| Hyponatraemia | 1,555 | 3.63.4–3.8 | signal |
| Anaemia | 5,244 | 3.33.2–3.4 | signal |
| Kidney injury | 7,837 | 3.23.1–3.3 | signal |
| Serious infection | 11,440 | 2.82.7–2.8 | signal |
| Thrombocytopenia | 2,978 | 2.52.4–2.6 | signal |
| Fall / fracture | 4,890 | 2.42.3–2.5 | signal |
| Neutropenia / agranulocytosis | 3,110 | 2.32.3–2.4 | signal |
| Venous thromboembolism | 2,718 | 2.32.3–2.4 | signal |
| Hypoglycaemia | 993 | 1.91.8–2.1 | raised |
| Myocardial infarction | 2,034 | 1.91.8–1.9 | raised |
| Interstitial lung disease | 870 | 1.71.6–1.8 | raised |
| Hyperglycaemia / diabetes | 3,126 | 1.71.6–1.7 | raised |
| Pancreatitis | 685 | 1.61.5–1.7 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Diarrhoea (diarrhea) | 8,241 | 2.4 2.3–2.4ROR 2.5 · calibrated p 0.813 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 2.3 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 8,132 | 2.7 2.6–2.7ROR 2.8 · calibrated p 0.689 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.2 · serious PRR 2.4 | no trial arm names this drug |
| Nausea | 7,889 | 1.9 1.8–1.9ROR 1.9 · calibrated p 0.902 | 1.9 EB05 1.8 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.0 | no trial arm names this drug |
| Fatigue (tiredness) | 7,881 | 1.9 1.8–1.9ROR 2.0 · calibrated p 0.919 | 1.9 EB05 1.8 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Death | 5,686 | 1.2 1.2–1.3ROR 1.2 · calibrated p 0.464 | 1.2 EB05 1.2 · IC025 +0.2 | Outcome field, not a reaction | age-adj. PRR 1.1 · serious PRR 1.0 | no trial arm names this drug |
| Pneumonia (lung infection) | 5,451 | 3.2 3.1–3.2ROR 3.3 · calibrated p 0.545 | 3.1 EB05 3.1 · IC025 +1.6 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.6 · serious PRR 2.5 | no trial arm names this drug |
| Headache | 5,081 | 1.5 1.5–1.5ROR 1.5 · calibrated p 0.661 | 1.5 EB05 1.5 · IC025 +0.5 | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.5 | no trial arm names this drug |
| Asthenia (weakness) | 5,070 | 2.5 2.4–2.6ROR 2.6 · calibrated p 0.776 | 2.5 EB05 2.4 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.9 · serious PRR 2.3 | no trial arm names this drug |
| Dizziness | 4,940 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.879 | 1.8 EB05 1.8 · IC025 +0.8 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.9 | no trial arm names this drug |
| Vomiting | 4,888 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.935 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 1.9 | no trial arm names this drug |
| Pain | 4,853 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.632 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.4 | no trial arm names this drug |
| Off label use (used outside approved label) | 4,684 | 1.0 1.0–1.0ROR 1.0 · calibrated p 0.306 | 1.0 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.0 · serious PRR 1.1 | no trial arm names this drug |
| Fall | 4,598 | 2.6 2.5–2.7ROR 2.6 · calibrated p 0.752 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.9 · serious PRR 2.2 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 4,462 | 0.6 0.6–0.6ROR 0.6 · calibrated p 0.089 | 0.6 EB05 0.6 · IC025 -0.7 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.8 · serious PRR 0.8 | no trial arm names this drug |
| Anaemia (low red blood cells) | 3,699 | 3.6 3.5–3.8ROR 3.7 · calibrated p 0.432 | 3.6 EB05 3.5 · IC025 +1.8 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.9 · serious PRR 3.0 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vaginal flatulence — n=183, PRR 279.4
- Appendicolith — n=206, PRR 221.5
- Female genital tract fistula — n=205, PRR 24.9
- Chronic kidney disease-mineral and bone disorder — n=109, PRR 20.8
- Radiculopathy — n=252, PRR 19.5
- Hyperparathyroidism secondary — n=219, PRR 17.5
- Infusion site discharge — n=144, PRR 16.9
- Nephrogenic anaemia — n=392, PRR 16.9
- Hyperphosphataemia — n=174, PRR 16.5
- Chronic sinusitis — n=278, PRR 14.8
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Potassium Chloride?
In FDA FAERS, the most frequently co-reported reaction terms for Potassium Chloride are diarrhoea, dyspnoea, nausea, fatigue, pneumonia, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Potassium Chloride have an FDA boxed warning?
No. The FDA label retrieved for Potassium Chloride has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Potassium Chloride causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 02707146-331f-4511-a187-0152fc8bca85, effective 20260724; matched on
openfda.generic_name.exact:"POTASSIUM CHLORIDE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 4873 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,197 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
POTASSIUM CHLORIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.